Defense Advanced Research Projects AgencyTagged Content List

Infectious Disease

Relating to ailments caused by pathogens

Showing 25 results for Disease + News RSS
11/15/2019
In a twist on how gene editing technology might be applied in the future, DARPA’s newest biotechnology funding opportunity aims to incorporate gene editors into detectors for distributed health biosurveillance and rapid, point-of-need diagnostics for endemic, emerging, and engineered pathogenic threats. The “Detect It with Gene Editing Technologies” (DIGET) program could help the Department of Defense maintain force readiness by informing rapid medical response and increasing the standard of care for troops, and preserve geopolitical stability by preventing the spread of infectious disease from becoming a driver of conflict.
03/30/2020
We find ourselves in pandemic times. The global population is under siege by an infectious virus new to humankind. It’s called Severe Acute Respiratory Syndrome Coronavirus 2, or SARS-CoV-2. It’s the causative agent of the pandemic disease designated COVID-19. This viral adversary knows no politics. It recognizes no national boundaries. It is unconcerned with anyone’s identity. All 7.8 billion of us are the same to the virus: we are all hosts suitable to commandeer to make copies of itself.
04/06/2020
Warfighters are travelers and thus suffer from travelers’ ailments including disrupted sleep cycles and limited access to safe food and water. Warfighters who have not slept well have lower alertness, weaker athletic performance, and greater disorientation. Current approaches to restoring wakefulness often lean on chemical methods that disrupt downstream sleep patterns and lead to exhaustion.
05/14/2020
In this episode of our Voices from DARPA podcast, Eric Van Gieson, a program manager since 2017 in the agency’s Biological Technologies Office (BTO), recounts how a boyhood fascination with DARPA ultimately led to his current role overseeing a portfolio of envelope-pushing programs. These include a program that seeks new diagnostic tools for perhaps the earliest-possible detection of exposure to pathogens, including SARS-CoV-2, the virus that causes COVID-19; an effort to identify and leverage the biomolecular bases underlying optimal performance in such roles as piloting aircraft or participating in special forces missions; research toward new personal-protection technologies that combine advanced featherweight fabrics with designed, bio-based agents applied directly to the body where they can neutralize injurious chemical and biological agents before they can do damage; and a bold biomedical strategy that stands a chance of replacing some medicine-based treatments (for conditions ranging from irritable bowel syndrome to post-traumatic stress disorder) with treatments based on the electrical stimulation of the peripheral nervous system, specifically the far-reaching vagus nerve.
06/12/2020
Antibiotic resistance is on the rise and is recognized by both the CDC1 and the U.S. Military2 as a current – and formidable – global health threat. The U.S Department of Defense (DoD) has long documented the warfighter’s outsized risk of exposure to infectious disease, including the increasing number of multi-drug resistant (MDR) organisms that have challenged military wound care in Iraq and Afghanistan3. Despite this looming crisis, there has been a notable exodus of pharmaceutical companies from the antibiotic space, as well as several high-profile failures of biotechnology companies focused on antibiotic development4.